Fondazione Ricerca Traslazionale
Quick facts
Phase 3 pipeline
- Olaparib tablet · Oncology
Olaparib inhibits poly(ADP-ribose) polymerase (PARP) enzymes, preventing DNA repair in cancer cells and causing cell death.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Fondazione Ricerca Traslazionale portfolio CI brief
- Fondazione Ricerca Traslazionale pipeline updates RSS
Frequently asked questions about Fondazione Ricerca Traslazionale
What is Fondazione Ricerca Traslazionale's pipeline?
Fondazione Ricerca Traslazionale has 1 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include Olaparib tablet.
Related
- Sector hub: All tracked pharma companies